We focus on developing small molecule drugs that address unmet clinical needs . Leveraging our high-precision AI drug discovery platform, we advance early-stage drug development and continuously deliver innovative treatment solutions for major diseases.

In addition to our existing core pipeline, we are actively expanding a diverse portfolio of research programs, targeting oncology, chronic diseases, and rare disorders to meet critical medical needs.

With the extensive expertise of our R&D team, we are actively exploring a broad range of novel and competitive small-molecule candidates. Our programs span diverse therapeutic areas including oncology, anti-fibrosis, and neurodegenerative diseases, driving product development from preclinical research through clinical trials.